BR100 Decreased By (-0.53%)
BR30 Decreased By (-0.98%)
KSE100 Decreased By (-0.46%)
KSE30 Decreased By (-0.43%)
AGHA 6.69 Increased By ▲ 0.01 (0.15%)
BECO 4.36 Decreased By ▼ -0.01 (-0.23%)
BML 56.25 Decreased By ▼ -1.07 (-1.87%)
BOP 30.12 Decreased By ▼ -0.23 (-0.76%)
CNERGY 13.00 Decreased By ▼ -0.12 (-0.91%)
CSIL 5.33 Decreased By ▼ -0.08 (-1.48%)
FCCL 52.38 Decreased By ▼ -0.41 (-0.78%)
FFL 14.57 Decreased By ▼ -0.15 (-1.02%)
FNEL 1.12 No Change ▼ 0.00 (0%)
KEL 6.12 Increased By ▲ 0.03 (0.49%)
KOSM 6.02 Increased By ▲ 0.29 (5.06%)
LOTCHEM 26.39 Decreased By ▼ -0.07 (-0.26%)
MLCF 91.80 Decreased By ▼ -1.36 (-1.46%)
NBP 164.20 Decreased By ▼ -0.46 (-0.28%)
NCPL 53.55 Decreased By ▼ -2.11 (-3.79%)
NPL 58.97 Decreased By ▼ -2.19 (-3.58%)
OGDC 315.00 Decreased By ▼ -1.73 (-0.55%)
PACE 9.90 Increased By ▲ 0.03 (0.3%)
PAEL 35.18 Decreased By ▼ -0.45 (-1.26%)
PIBTL 14.65 Decreased By ▼ -0.03 (-0.2%)
PPL 222.72 Decreased By ▼ -4.19 (-1.85%)
PRL 91.39 Decreased By ▼ -1.63 (-1.75%)
PTC 59.01 Decreased By ▼ -1.25 (-2.07%)
SSGC 23.35 Decreased By ▼ -0.46 (-1.93%)
TBL 8.75 No Change ▼ 0.00 (0%)
TELE 7.70 Decreased By ▼ -0.10 (-1.28%)
TPL 22.20 Decreased By ▼ -0.15 (-0.67%)
TPLP 12.61 Decreased By ▼ -0.36 (-2.78%)
TREET 21.99 Decreased By ▼ -0.17 (-0.77%)
TRG 56.50 Decreased By ▼ -0.06 (-0.11%)
By

GENEVA: The AstraZeneca-Oxford Covid-19 vaccine can be used for people aged over 65, and also where coronavirus variants of concern are circulating, WHO experts said Wednesday, soothing fears about the jab.

The World Health Organization’s 15-member Strategic Advisory Group of Experts on Immunization (SAGE) issued interim recommendations for when and how to use the two-shot vaccine, which has yet to receive WHO emergency use authorisation.

The announcement came after the vaccine suffered several setbacks, raising questions about whether it was appropriate to use it on older people, or in places where a variant of the virus first found in South Africa is circulating.

SAGE chief Alejandro Cravioto acknowledged the lack of data on the vaccine’s efficacy for people aged over 65, which has prompted a number of countries to withhold recommending its use in older people — who are by far the most vulnerable to the virus.

But, he told journalists, “we feel that the response of this group cannot be any different from groups of a younger age”.

SAGE, he said, recommends “for the vaccine to be used for 18 years and above without an upper age limit”.

He said the experts were eagerly awaiting more specific data on the efficacy of the vaccine in people over 65, but said it “would not be appropriate” to wait with its recommendations.

“We have thousands of people dying,” he stressed.

Comments

Comments are closed for this article.